Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Investigate the Safety and Clinical Effect of Nexagon® as a Topical Treatment for Subjects With a Diabetic Foot Ulcer (DUNE) (DUNE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01490879
Recruitment Status : Completed
First Posted : December 13, 2011
Last Update Posted : May 1, 2014
Sponsor:
Information provided by (Responsible Party):
OcuNexus Therapeutics, Inc.

Brief Summary:
This study is for Type I or Type II diabetic subjects with with a diabetic foot ulcer. The study is being done to determine if Nexagon® plus standard of care is more effective than placebo plus standard of care. Standard of care will include debridement of the ulcer, standardized dressings and standardized off-loading using a Removable Cast Walker.

Condition or disease Intervention/treatment Phase
Diabetic Foot Ulcers Drug: Nexagon® Low Dose Drug: Nexagon® Medium Dose Drug: Nexagon® High Dose Drug: Nexagon® vehicle Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 168 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Prospective, Double-blind, Vehicle-controlled, Dose-ranging, Multi-center Study to Assess the Safety and Clinical Effect of Nexagon® in the Treatment of Subjects With a Diabetic Foot Ulcer
Study Start Date : July 2012
Actual Primary Completion Date : February 2014
Actual Study Completion Date : April 2014

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Nexagon® Low Dose
Twice weekly applications of Nexagon® low dose in addition to off-loading using a Removable Cast Walker
Drug: Nexagon® Low Dose
Twice weekly, topical application of Nexagon® low dose in addition to a Removable Cast Walker

Experimental: Nexagon® Medium Dose
Twice weekly applications of Nexagon® medium dose in addition to off-loading using a Removable Cast Walker
Drug: Nexagon® Medium Dose
Twice weekly, topical application of Nexagon® medium dose in addition to a Removable Cast Walker

Experimental: Nexagon® High Dose
Twice weekly applications of Nexagon® high dose in addition to off-loading using a Removable Cast Walker
Drug: Nexagon® High Dose
Twice weekly, topical application of Nexagon® high dose in addition to a Removable Cast Walker

Placebo Comparator: Nexagon® vehicle
Twice weekly applications of Nexagon® vehicle in addition to off-loading using a Removable Cast Walker
Drug: Nexagon® vehicle
Twice weekly, topical application of Nexagon® vehicle in addition to a Removable Cast Walker




Primary Outcome Measures :
  1. Incidence of Reference Diabetic Foot Ulcer (RDFU) complete closure determined by Investigator Assessment [ Time Frame: Within 12 weeks ]

Secondary Outcome Measures :
  1. Percentage change in RDFU surface area [ Time Frame: Within 12 weeks ]
  2. Time to RDFU complete closure [ Time Frame: Within 12 weeks ]
  3. Percentage of granulation tissue in RDFU [ Time Frame: 12 weeks ]
  4. Incidence of ulcer recurrence [ Time Frame: 12 weeks post-closure ]
  5. Incidence of adverse events [ Time Frame: 12 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Diagnosis of diabetes mellitus (Type I or II)
  2. HbA1c of less than or equal to 12.0%
  3. Diagnosis of neuropathic foot ulcer with partial or complete neuropathy
  4. Cutaneous ulcer on the plantar or dorsal aspect of the foot or toe that is greater or equal to 1.0cm2 and less than or equal to 8.0 cm2 in area at the end of the screening period and is full thickness with no exposed ligament, tendon, joint capsule or bone. Surface area will be measured by digital planimetry.
  5. The Medical Monitor(or delegate)must confirm that the reference diabetic foot ulcer (RDFU)is suitable for inclusion after reviewing digital photographs
  6. Wound bed consisting of completely viable tissue or one where completely viable tissue will be achieved by the end of the screening period.
  7. An Ankle Branchial Index (ABI) of greater or equal to 0.80 in concert with a bi- or tri-phasic Doppler flow pattern; or adequate circulation as demonstrated by any of the following methods: peri-wound transcutaneous partial pressure oxygen (TcpO2)greater or equal to 40 mmHg; or a toe pressure of greater or equal to 40 mmHg; or skin perfusion pressure of greater or equal to 40 mmHg.
  8. Ulcer present for 4 weeks or more or less than or equal to 12 months.
  9. Willing to wear a Removable Cast Walker (RCW) between study visits for the duration of the study.
  10. Signed informed consent form.

Exclusion Criteria:

  1. Any unstable medical condition that would cause the study to be detrimental to the subject.
  2. Decrease in RDFU size by more than 40% or increase in the ulcer size by more than 40% during the 14-day screening period as measured by digital planimetry.
  3. Ulcers caused primarily by untreated vascular insufficiency or ulcers with an etiology not related to diabetes.4. Ulcers above the ankle.

5. Ulcers that cannot be effectively off-loaded using the cast walker and sole insert provided in this study (ulcers not located on the weight bearing surface of the foot do not require off-loading).

6. Ulcers on the toes not accessible for photography (e.g. in the web space). 7. Presence of other ulcers within 2cm of the perimeter of the RDFU. 8. BMI > 45 9. Cannot tolerate or will not comply with the off-loading method, or non-compliance with standard or care.

10.The RDFU is infected (clinical assessment of infection)and/or biopsy proof of greater than 100,000 organisms per gram of tissue during the screening period.

11. Subjects presenting with the clinical characteristics of cellulitis at the ulcer site. 12. Necrosis, purulence, or sinus tracts that cannot be removed by debridement.13. Definite or suspected osteomyelitis within any wound located anywhere on the subjects body.14. Acute Charcot's neuroarthropathy as determined by clinical and/or previous radiographic examination.

15. Severe Charcot deformity or rocker bottom foot with an associated plantar mid-foot or heel ulcer.

16. Revascularization surgery on the leg with the wound to be treated less than or equal to 4 weeks prior to the start of the screening period.

17. Requirement for concurrent topical antimicrobials to treat the RDFU after the end of the screening period.

18. Received dermal substitute or living skin equivalent (e.g. Dermagraft® or Apligraf®) within 14 days prior of the start of the screening period.

19. Severe complications of diabetes that in the opinion of the Investigator could interfere with wound healing or impede the subject's participation.

20. Subjects on concurrent immunosuppressive therapy to include oral corticosteroid therapy equivalent to greater than 5 mg/day of prednisone.

21. Any history of radiation therapy to the foot. 22. Female subjects who are pregnant or lactating. 23. Pre-menopausal women not using effective birth control methods as determined by the Investigator. 24. Life expectancy of < 12 months. 25. Subjects on renal replacement therapy. 26. Cancer within the last 3 years except basal and squamous cell carcinoma. 27. Cancer within the RDFU


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01490879


Locations
Show Show 25 study locations
Sponsors and Collaborators
OcuNexus Therapeutics, Inc.
Investigators
Layout table for investigator information
Principal Investigator: David G Armstrong, DPM MD PhD S.A.L.S.A. , University of Arizona, Tucson, AZ
Layout table for additonal information
Responsible Party: OcuNexus Therapeutics, Inc.
ClinicalTrials.gov Identifier: NCT01490879    
Other Study ID Numbers: NEX-ULC-011
First Posted: December 13, 2011    Key Record Dates
Last Update Posted: May 1, 2014
Last Verified: April 2014
Keywords provided by OcuNexus Therapeutics, Inc.:
DFU
Diabetic Foot Ulcer
Ulcers
Foot Ulcers
chronic wound
wounds
Nexagon
CoDa
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetic Foot
Foot Ulcer
Ulcer
Pathologic Processes
Diabetic Angiopathies
Vascular Diseases
Cardiovascular Diseases
Leg Ulcer
Skin Ulcer
Skin Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Diabetic Neuropathies
Foot Diseases